Related Experiment Video
Updated: Jul 11, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line
Ning Zhang1, Kaixiong Tao, Tao Huang
1Department of General Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. zhangning0823@126.com
Abstract:
To investigate the effect of meloxicam, a selected NSAIDs, on cell growth, expression of VEGF and angiopointin-2 (Ang-2) protein in HT-29 cell line, cultured HT-29 cells were treated with meloxicam of various concentrations for various lengths of time. The proliferation of HT-29 was detected by cell counting kit-8 (CCK-8), the cell cycle was determined by flow cytometer and the levels of VEGF and Ang-2 protein in supernatants were examined by enzyme linked immunosorbent assay (ELISA). The mRNA expressions of VEGF and Ang-2 in cultured HT-29 were determined by real-time quantitative reverse-transcription polymerase chain reaction. Our results showed that treatment of meloxicam of different concentrations and for various lengths of time had a cytotoxicic effect on the cell proliferation of HT-29 cells in a concentration-dependant and time-dependant manner. Cell cycle analysis showed that the cells were mainly blocked in G0/G1 phase. The VEGF and Ang-2 protein levels in supernatants of the culture medium were decreased gradually in a concentration-dependent or time-dependent fashion. The mRNA expression of cox-2, VEGF and Ang-2 showed a gradual and concentration-dependent reduction. It is concluded that meloxicam can reduce the expression of VEGF and Ang-2 at the protein and mRNA level in colon carcinoma cell line.
Insights
Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), inhibits colon cancer cell growth by reducing vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) at both protein and mRNA levels.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Colon carcinoma is a significant global health concern.
- Vascular Endothelial Growth Factor (VEGF) and Angiopoietin-2 (Ang-2) are key regulators of angiogenesis in cancer.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) like meloxicam have shown potential anti-cancer properties.
Purpose of the Study:
- To investigate the effects of meloxicam on HT-29 colon cancer cell line.
- To determine the impact of meloxicam on cell proliferation, cell cycle, and the expression of VEGF and Ang-2.
- To explore the molecular mechanisms underlying meloxicam's action in colon carcinoma.
Main Methods:
- HT-29 cells were treated with varying concentrations and durations of meloxicam.
- Cell proliferation was assessed using Cell Counting Kit-8 (CCK-8).
- Cell cycle analysis was performed via flow cytometry.
- VEGF and Ang-2 protein levels were quantified using ELISA.
- mRNA expression of VEGF, Ang-2, and COX-2 was determined by real-time quantitative reverse-transcription polymerase chain reaction.
Main Results:
- Meloxicam exhibited a concentration- and time-dependent cytotoxic effect on HT-29 cell proliferation.
- Cell cycle analysis revealed a predominant arrest in the G0/G1 phase.
- Both VEGF and Ang-2 protein levels in the supernatant decreased with increasing meloxicam concentration and treatment time.
- A significant reduction in the mRNA expression of COX-2, VEGF, and Ang-2 was observed in a concentration-dependent manner.
Conclusions:
- Meloxicam demonstrates anti-proliferative effects on the HT-29 colon carcinoma cell line.
- Meloxicam significantly downregulates the expression of VEGF and Ang-2 at both protein and mRNA levels.
- These findings suggest that meloxicam may exert its anti-cancer effects, in part, by inhibiting angiogenesis-related factors.
